Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now.
Syndax Pharmaceuticals Inc (SNDX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.00 | 3,000 | $0.00 | 93,746 | 2025-05-19 | Filing | |
| $9.00 | 11,765 | $105,826.18 | 35,165 | 2025-05-16 | Filing | |
| $8.99 | 5,000 | $44,950.00 | 79,000 | 2025-05-19 | Filing | |
| $9.11 | 10,000 | $91,120.00 | 100,000 | 2025-05-19 | Filing | |
| $20.03 | 1,250 | $25,037.25 | 52,623 | 2024-06-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.03 | 17,159 | $360,819.45 | 491,690 | 2026-02-09 | Filing | |
| $21.03 | 3,410 | $71,705.48 | 140,429 | 2026-02-09 | Filing | |
| $20.62 | 7,412 | $152,835.44 | 508,849 | 2026-02-06 | Filing | |
| $20.62 | 2,082 | $42,930.84 | 143,839 | 2026-02-06 | Filing | |
| $16.41 | 157,307 | $2,582,021.37 | 298,661 | 2025-09-08 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,822,579 | $89,295,445 | 0% | |
| 2. | 1,737,141 | $40,579,614 | 0% | |
| 3. | 1,494,645 | $34,914,908 | 0.01% | |
| 4. | 1,316,806 | $30,760,588 | 6.46% | |
| 5. | 1,153,662 | $26,949,545 | 0% |
News See All
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. [Operator Instructions].
11 Best Cancer Stocks to Invest In Now
Pharmaceutical companies are a blend of defensive income plays and growth opportunities.
BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory
We came across a bullish thesis on Syndax Pharmaceuticals, Inc. on BioEquity Watch’s Substack.
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks with huge upside potential.
10 Most Promising Stocks with Huge Upside Potential
On November 25, Matt Powers, managing partner of Powers Advisory Group, joined CNBC's 'Squawk Box' to discuss what to make of recent volatility and why he believes that value will start to pick up.
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating
On November 12, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) saw JPMorgan reduce its price target from $40 to $33, while reiterating its “Overweight” rating.
10 Best Small-Cap Biotech Stocks to Buy According to Analysts
Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention.
Hedge Fund Resource Center